Genlight closes Series C and D funding rounds for brain-computer interface platform

• Shanghai Jiachen Private Equity Fund Management portfolio company Genlight closed successive Series C and Series D financing rounds.
• Genlight develops a full-stack brain-computer interface platform spanning smart hardware, multimodal data, and large AI models.
• Pipeline targets major neurological disorders; flagship Epilcure implantable neurostimulation system entered China’s innovative-device review in 2022.
• By 2025, pivotal Epilcure trial enrolled 110 subjects; total clinical implantations exceeded 120.
• Genlight is pursuing FDA and CE registrations via hubs in Hangzhou and Singapore, alongside international clinical collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Jiachen Private Equity Fund Management Co Ltd published the original content used to generate this news brief on October 10, 2026, and is solely responsible for the information contained therein.